| Literature DB >> 356971 |
R G Hahn, N R Temkin, E D Savlov, C Perlia, G L Wampler, J Horton, J Marsh, P P Carbone.
Abstract
One hundred and sixty-five patients with advanced renal cell cancer were evaluable for combination or single-agent therapy with methyl-CCNU, vinblastine, and medroxyprogesterone. A low order or response was observed, and these agents were not proven effective as treatment for metastatic renal cell cancer. Performance status and a relatively long symptom-free interval from primary tumor to metastatic disease were found to be the most prognostically significant factors for survival.Entities:
Keywords: Biology; Cancer; Clinic Activities; Clinical Research; Contraception; Contraceptive Agents, Female--therapeutic use; Contraceptive Agents, Progestin--therapeutic use; Contraceptive Agents--therapeutic use; Diseases; Family Planning; Medroxyprogesterone Acetate--therapeutic use; Neoplasms; Physiology; Prospective Studies; Renal Effects; Research Methodology; Studies; Treatment; Urogenital Effects; Urogenital System
Mesh：
Substances：
Year: 1978 PMID： 356971
Source DB: PubMed Journal: Cancer Treat Rep ISSN： 0361-5960